Several studies have shown that other SGLT2 inhibitors (ipragliflozin and luseogliflozin) alleviate hepatic steatosis or steatohepatitis in obese type 2 diabetic mice or rats [13–16]. This evidence concerns the gene SLC5A2 and fatty liver disease.